Expression of metabolically targeted biomarkers in endometrial carcinoma

Gynecologic Oncology

Volumn 116, Issue 1, 2010, Pages 21-27

  Wahl, Heather ^a   Daudi, Sayeema ^a   Kshirsagar, Malti ^a   Griffith, Kent ^b   Tan, Lijun ^a   Rhode, Jennifer ^a   Liu, J Rebecca ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Endometrial carcinoma; Glut1; pAkt; pmTOR

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; DEOXYGLUCOSE; GLUCOSE TRANSPORTER 1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAPAMYCIN;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL DEATH; CELL GROWTH; CONTROLLED STUDY; CYTOSTASIS; ENDOMETRIUM CARCINOMA; GLUCOSE TRANSPORT; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CISPLATIN; DEOXYGLUCOSE; DRUG DELIVERY SYSTEMS; DRUG SYNERGISM; ENDOMETRIAL NEOPLASMS; FEMALE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SIROLIMUS; TUMOR MARKERS, BIOLOGICAL;

EID: 70749115376     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2009.10.040     Document Type: Article

References (30)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics, 2008. CA Cancer J. Clin. 58 (2008) 71-96
2. Warburg O. On the origin of cancer cells. Science 123 (1956) 309-314
3. Rastogi S., Banerjee S., Chellappan S., and Simon G.R. Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines. Cancer Lett. 257 (2007) 244-251
4. Tsukioka M., Matsumoto Y., Noriyuki M., Yoshida C., Nobeyama H., Yoshida H., et al. Expression of glucose transporters in epithelial ovarian carcinoma: correlation with clinical characteristics and tumor angiogenesis. Oncol. Rep. 18 (2007) 361-367
5. Plas D.R., Talapatra S., Edinger A.L., Rathmell J.C., and Thompson C.B. Akt and Bcl-xL promote growth factor-independent survival through distinct effects on mitochondrial physiology. J. Biol. Chem. 276 (2001) 12041-12048
6. Rathmell J.C., Elstrom R.L., Cinalli R.M., and Thompson C.B. Activated Akt promotes increased resting T cell size, CD28-independent T cell growth, and development of autoimmunity and lymphoma. Eur. J. Immunol. 33 (2003) 2223-2232
7. Barthel A., Okino S.T., Liao J., Nakatani K., Li J., Whitlock Jr. J.P., et al. Regulation of GLUT1 gene transcription by the serine/threonine kinase Akt1. J. Biol. Chem. 274 (1999) 20281-20286
8. Singh D., Banerji A.K., Dwarakanath B.S., Tripathi R.P., Gupta J.P., Mathew T.L., et al. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol. 181 (2005) 507-514
9. http://clinicaltrials.gov/ct2/show/NCT00247403?intr=%22Deoxyglucose%22&rank=2. In; 2008.
10. Elstrom R.L., Bauer D.E., Buzzai M., Karnauskas R., Harris M.H., Plas D.R., et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 64 (2004) 3892-3899
11. Edinger A.L., and Thompson C.B. Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. Mol. Biol. Cell 13 (2002) 2276-2288
12. Guertin D.A., and Sabatini D.M. An expanding role for mTOR in cancer. Trends Mol. Med. 11 (2005) 353-361
13. Guertin D.A., and Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 12 (2007) 9-22
14. Goldman N.A., Katz E.B., Glenn A.S., Weldon R.H., Jones J.G., Lynch U., et al. GLUT1 and GLUT8 in endometrium and endometrial adenocarcinoma. Mod. Pathol. 19 (2006) 1429-1436
15. Kanamori Y., Kigawa J., Itamochi H., Shimada M., Takahashi M., Kamazawa S., et al. Correlation between loss of PTEN expression and Akt phosphorylation in endometrial carcinoma. Clin. Cancer Res. 7 (2001) 892-895
16. Darb-Esfahani S., Faggad A., Noske A., Weichert W., Buckendahl A.C., Muller B., et al. Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J. Cancer Res. Clin. Oncol. 135 (2009) 933-941
17. Bae-Jump V.L., Zhou C., Boggess J.F., and Gehrig P.A. Synergistic effect of rapamycin and cisplatin in endometrial cancer cells. Cancer 115 (2009) 3887-3896
18. Oda K., Okada J., Timmerman L., Rodriguez-Viciana P., Stokoe D., Shoji K., et al. PIK3CA cooperates with other phosphatidylinositol 3′-kinase pathway mutations to effect oncogenic transformation. Cancer Res. 68 (2008) 8127-8136
19. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82 (1990) 1107-1112
20. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., and Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods 139 (1991) 271-279
21. Sun Q., Zheng Y., Liu Q., and Cao X. Rapamycin reverses TLR4 signaling-triggered tumor apoptosis resistance by disrupting Akt-mediated Bcl-xL upregulation. Int. Immunopharmacol. 8 (2008) 1854-1858
22. Young C.D., and Anderson S.M. Sugar and fat-that's where it's at: metabolic changes in tumors. Breast Cancer Res. 10 (2008) 202
23. Pectasides D., Pectasides E., and Economopoulos T. Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat. Rev. 33 (2007) 177-190
24. Hayes M.P., Douglas W., and Ellenson L.H. Molecular alterations of EGFR and PIK3CA in uterine serous carcinoma. Gynecol. Oncol. 113 (2009) 370-373
25. Gadducci A., Tana R., Cosio S., Fanucchi A., and Genazzani A.R. Molecular target therapies in endometrial cancer: from the basic research to the clinic. Gynecol. Endocrinol. 24 (2008) 239-249
26. Sabatini D.M. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 6 (2006) 729-734
27. Zhu Z., Jiang W., and McGinley J.N. Thompson HJ. 2-Deoxyglucose as an energy restriction mimetic agent: effects on mammary carcinogenesis and on mammary tumor cell growth in vitro. Cancer Res. 65 (2005) 7023-7030
28. Maschek G., Savaraj N., Priebe W., Braunschweiger P., Hamilton K., Tidmarsh G.F., et al. 2-deoxy-d-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res. 64 (2004) 31-34
29. http://clinicaltrials.gov/ct2/results?intr=%22Deoxyglucose%22. In; 2008.
30. Ralser M., Wamelink M.M., Struys E.A., Joppich C., Krobitsch S., Jakobs C., et al. A catabolic block does not sufficiently explain how 2-deoxy-d-glucose inhibits cell growth. Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 17807-17811